(Q36840684)
Statements
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review) (English)
Laura Ferrer-Soler
Alejandro Vazquez-Martin
Rafael De Llorens